Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascul...( Initiates Phase I Clinical Trial to...),Health

Initiates Phase I Clinical Trial to Evaluate Ultra-Pure Ethyl EPA-Niacin

for Treatment of Niacin- Induced Flushing

LONDON, November 29 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced a phase I clinical safety and efficacy trial in volunteers. The trial will evaluate the co-administration of ultra-pure ethyl EPA and niacin on niacin induced flushing. Flushing is a common side effect of niacin treatment which significantly limits patient compliance.

Niacin is a treatment is used to increase High Density Lipoprotein (HDL) and modestly decrease triglyceride levels in dyslipidemia or cholesterol management. Ultra-pure ethyl EPA has been prescribed in Japan for over 15 years for the treatment of triglyceride lowering. Ultra-pure ethyl EPA is known to have several additional beneficial effects in cardiovascular disease.

Rick Stewart, Chief Executive Officer commented, "The initiation of this study is significant because it marks the commencement of Amarin's cardiovascular development program and potentially addresses a major medical need. Niacin is a valuable addition to the treatment of dyslipidemia but its principal drawback is flushing."

Mr. Stewart continued, "Amarin's cardiovascular program capitalizes on the known therapeutic benefits of ultra-pure EPA in cardiovascular disease and is a logical extension from Amarin's existing therapeutic base for ultra-pure EPA and its derivatives. By using ultra-pure EPA and niacin together, both HDL and triglycerides can be managed. We believe this combination can be a useful therapeutic proposition. We are fortunate to have the know-how, the intellectual property, the resources and th
'/>"/>